|
|
Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death.Growth hormone treatment probably did not contribute to new tumour development.Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom.This cohort must remain under long term review. |
|